Blog

In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in...

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study...

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first...

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....

https://www.houstonmethodist.org/leading-medicine-blog/articles/2022/sep/first-biomarkers-identified-to-measure-als-disease-progression-a...

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...

NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the...